Strongbridge Biopharma (NASDAQ:SBBP) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday.
According to Zacks, “Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing’s syndrome, COR-004 and COR-005 to treat acromegaly, BP-2001, the treatment of diabetes which are in different clinical trial. Strongbridge Biopharma PLC is based in Trevose, Pennsylvania. “
A number of other research firms have also recently issued reports on SBBP. BidaskClub upgraded shares of Strongbridge Biopharma from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 11th. ValuEngine cut shares of Strongbridge Biopharma from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Cantor Fitzgerald started coverage on shares of Strongbridge Biopharma in a report on Tuesday, December 5th. They set a “buy” rating and a $14.00 price target for the company. Finally, HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Strongbridge Biopharma in a report on Wednesday, November 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $12.81.
Shares of Strongbridge Biopharma (NASDAQ SBBP) opened at $7.85 on Wednesday. The stock has a market cap of $299.03, a price-to-earnings ratio of -2.31 and a beta of 2.60. Strongbridge Biopharma has a fifty-two week low of $2.10 and a fifty-two week high of $8.85. The company has a quick ratio of 4.61, a current ratio of 4.70 and a debt-to-equity ratio of -1.89.
Strongbridge Biopharma (NASDAQ:SBBP) last issued its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.46) by $0.07. analysts anticipate that Strongbridge Biopharma will post -2.86 EPS for the current fiscal year.
A number of hedge funds have recently added to or reduced their stakes in SBBP. Rhumbline Advisers bought a new stake in Strongbridge Biopharma during the second quarter valued at about $154,000. California State Teachers Retirement System bought a new stake in Strongbridge Biopharma during the second quarter valued at about $277,000. Teachers Advisors LLC bought a new stake in Strongbridge Biopharma during the second quarter valued at about $297,000. Bank of New York Mellon Corp bought a new stake in Strongbridge Biopharma during the second quarter valued at about $331,000. Finally, Schwab Charles Investment Management Inc. bought a new stake in Strongbridge Biopharma during the second quarter valued at about $332,000. Institutional investors own 63.96% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Zacks Investment Research Lowers Strongbridge Biopharma (SBBP) to Hold” was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://transcriptdaily.com/2018/01/19/zacks-investment-research-lowers-strongbridge-biopharma-sbbp-to-hold.html.
About Strongbridge Biopharma
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.